Based on these results, from the viewpoint of early prediction of Lenvatinib treatment response, we further investigated the association between changes in serum levels of FGF 19 and Ang-2 at 4 weeks and treatment response in terms of PFS in HCC patients on Lenvatinib treatment. The gene discussed is FGF19; the disease is hepatocellular carcinoma.